拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

盘后交易 11-22 18:29:07 EST

64.26

+0.81

+1.28%

盘后64.26

+0.000.00%

16:37 EST

最高64.46	最低63.78	成交量130.44万
今开63.88	昨收63.45	日振幅1.07%
总市值122.47亿	流通市值115.15亿	总股本1.91亿
成交额8,378万	换手率0.73%	流通股本1.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":64.26,"timestamp":1732309200000,"preClose":63.45,"halted":0,"volume":1304418,"hourTrading":{"tag":"盘后","latestPrice":64.26,"preClose":64.26,"latestTime":"16:37 EST","volume":115093,"amount":7395868.123489999,"timestamp":1732311449289},"delay":0,"floatShares":179189906,"shares":190583016,"eps":1.68037,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.81,"latestTime":"11-22 18:29:07 EST","open":63.88,"high":64.46,"low":63.78,"amount":83779402.74156,"amplitude":0.010717,"askPrice":64.6,"askSize":477,"bidPrice":64,"bidSize":30,"shortable":3,"etf":0,"ttmEps":1.68037,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732323600000},"adr":0,"listingDate":932702400000,"adjPreClose":63.45,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":63.45,"preClose":63.45,"latestTime":"07:12 EST","volume":8,"amount":510.38,"timestamp":1732277552567},"postHourTrading":{"tag":"盘后","latestPrice":64.26,"preClose":64.26,"latestTime":"16:37 EST","volume":115093,"amount":7395868.123489999,"timestamp":1732311449289},"volumeRatio":0.790472,"impliedVol":0.3284,"impliedVolPercentile":0.6032},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"2481508022","title":"美国研究综述-塞拉尼斯公司、Disc Medicine、Editas Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2481508022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481508022?lang=zh_cn&edition=full","pubTime":"2024-11-05 20:32","pubTimestamp":1730809940,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对塞拉尼斯公司、Disc Medicine 和 Editas Medicine 等几家美国上市公司的评级和目标价。* Disc Medicine Inc   ：雷蒙德-詹姆斯将其评级从 \"跑赢大盘 \"上调至 \"强力买入\"。* Editas Medicine Inc   ：雷蒙德-詹姆斯将其评级从 \"跑赢大市 \"下调至 \"跑赢大市\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4109","ARES","CRUS","CW","EGHT","CNP","BOWL","BCRX","CRGY","LU2087625088.SGD","CE","CHH","BK4178","DG","AIG","AFL","LU1699723380.USD","ATUS","CEG","BFAM","ABG","CAMP","LNG","BKNG","ADVM","CNC","AMG","LU2065169927.USD","CBT","ARHS","CAR","CRBG","CDNA","CHE","IE00BVYPNW00.USD","IE00BKVL7J92.USD","HIMS","AN","BMRN","CBLL","CI","CSTL","BWIN","CMS","LU0289739699.SGD","LU1496350502.SGD","BK4208","AWI","CC"],"gpt_icon":1},{"id":"2481541559","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481541559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481541559?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","CI","NYT","EGHT","FIS","FOXA","OMI","ARES","RL","HIMS","GKOS","NMRA","ATUS","CSTL","LU0971096721.USD","INSP","SLAB","LU0320765489.SGD","MDGL","LU1489326972.SGD","BK4106","PTGX","LU0149725797.USD","BMRN","ILMN","LU1363072403.SGD","BWIN","KROS","AMG","LU0949170772.SGD","LU0266512127.USD","LU1244550221.USD","MAR","CMS","BEN","SHAK","LU","IE00BZ1G4Q59.USD","EVER","ST","CAMP","SM","RZLT","FRPT","AWI","EDIT","LSCC"],"gpt_icon":1},{"id":"2481415545","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481415545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481415545?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BWIN","EGHT","ILMN","NYT","RL","GKOS","BMRN","AWI","LU","LU1363072403.SGD","RZLT","IE00BZ1G4Q59.USD","IRON","MDGL","PTGX","CI","LU1489326972.SGD","AMG","LU0971096721.USD","BK4106","FOXA","NMRA","LU0149725797.USD","MAR","FIS","LU1244550221.USD","OMI","FRPT","INSP","EDIT","SHAK","BEN","LU0320765489.SGD","CAMP","SLAB","EVER","LSCC","SM","ATUS","LU0266512127.USD","ST","CSTL","CMS","LU0949170772.SGD","KROS","ARES"],"gpt_icon":1},{"id":"2480730058","title":"拜玛林制药2024财年第三财季实现净利润1.06亿美元，同比增加162.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480730058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480730058?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563252,"startTime":"0","endTime":"0","summary":"11月3日，拜玛林制药公布财报，公告显示公司2024财年第三财季净利润为1.06亿美元，同比增加162.51%；其中营业收入为7.42亿美元，同比增加26.62%，每股基本收益为0.56美元。从资产负债表来看，拜玛林制药总负债14.38亿美元，其中短期债务0.00美元，资产负债比为4.77，流动比率为4.27。机构评级：截至2024年11月3日，当前有25家机构对拜玛林制药目标价做出预测，其中目标均价为96.72美元，其中最低目标价为65.00美元，最高目标价为127.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000111a20f7af3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000111a20f7af3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN"],"gpt_icon":0},{"id":"1159145068","title":"异动解读 | 拜玛林制药公司领跌生物科技股 公司业绩超预期但长期前景受质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1159145068","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159145068?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:36","pubTimestamp":1730295368,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)今日盘中大跌5.21%,引发市场广泛关注。尽管公司刚刚公布的上一季度业绩超出预期,但分析师对公司长期增长前景下调评级和目标价,成为拖累该股走低的主要原因。\n\n根据财报显示,拜玛林制药上季每股收益为0.55美元,高于分析师预期的0.52美元。营收同比增长28.3%至7.46亿美元,也超过了分析师的预期。公司旗舰产品在多个治疗领域表现出色,拉动了业绩增长。\n\n但与此同时,多家分析机构对公司的长期增长前景表示质疑。路透数据显示,有分析师将该股目标价下调至105美元,另有分析师直接下调公司评级。市场忧虑公司核心药品未来销售可能放缓,且新产品线研发进展缓慢,长期发展动力不足。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0},{"id":"2479834477","title":"拜玛林制药盘中异动 大幅下挫5.21%报66.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479834477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479834477?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:31","pubTimestamp":1730295076,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时31分，拜玛林制药股票出现波动，股价大幅下挫5.21%。截至发稿，该股报66.27美元/股，成交量4.0672万股，换手率0.02%，振幅0.52%。拜玛林制药股票所在的生物技术行业中，整体跌幅为0.30%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213117a1face5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213117a1face5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4139","BMRN","IE00B19Z3581.USD","BK4566"],"gpt_icon":0},{"id":"2479207021","title":"美国研究综述-Agilon Health、Alphabet、Crocs","url":"https://stock-news.laohu8.com/highlight/detail?id=2479207021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479207021?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:12","pubTimestamp":1730293926,"startTime":"0","endTime":"0","summary":"    路透10月30日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Agilon Health、Alphabet 和 Crocs。要闻 * Agilon Health Inc   ：花旗集团将其评级从 \"中性 \"下调至 \"卖出\"。* Alphabet Inc   ：Seaport Research Partners将其评级从中性上调至买入 * Crocs Inc   ：Raymond James将其评级从 \"跑赢大盘 \"下调至 \"市场表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e47c78d33fac7d6c9f981fc82a9d4a91","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBNA","BK4227","CNC","ANET","BMRN","BWFG","CWH","BK4585","CAC","CALX","ATI","BK4096","LU0823421333.USD","ADC","ALSN","CZR","AMT","LU","AXTA","CHPT","ALHC","IE00BZ1G4Q59.USD","ATRC","BYD","BY","CAKE","IE00B19Z4B17.USD","APP","ATGE","BK4574","BMEA","AESI","AJG","BP","ACA","LU0211328371.USD","TXG","SKY","ABG","CECO","PYPL","BK4539","BRO","AGL","ALNY","AWI"],"gpt_icon":1},{"id":"2479124485","title":"美国研究综述-Alphabet、Arthur J. Gallagher & Co、Leggett & Platt","url":"https://stock-news.laohu8.com/highlight/detail?id=2479124485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479124485?lang=zh_cn&edition=full","pubTime":"2024-10-30 14:34","pubTimestamp":1730270081,"startTime":"0","endTime":"0","summary":"    路透10月30日 - 华尔街证券分析师周三调整了对Alphabet、Arthur J. Gallagher & Co和Leggett & Platt等多家美国上市公司的评级和目标价。* Arthur J. Gallagher & Co：TD Cowen 将目标价从 288 美元上调至 295 美元 * Leggett & Platt Inc   ：Piper Sandler 将其评级从 \"减持 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"86620ca5f985192b0de68ba1fc9648ed","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0265550359.USD","GLW","VRTX","QRVO","LU2468319806.SGD","LEG","PRO","GOOG","SYY","IE00BN0W2V16.EUR","SYK","WM","SGXZ31699556.SGD","AJG","BMRN","LU0127658192.USD","UBER","GOOGL","TXG","IE0004086264.USD","LU","XRX","RSG","LSTR","LU2272731865.HKD","EA","ZBRA","DHI","CMG","LU0528227936.USD","TWO","SAFE","WERN","BK4161","MDLZ","LU2362541273.HKD","LU1093756168.USD","IE00BFSS8Q28.SGD","CZR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2089279066.USD","ESAB","BK4567","LU1366333091.USD"],"gpt_icon":1},{"id":"2479673213","title":"BioMarin Pharmaceutical Inc 报告截至 1 月 1 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2479673213","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479673213?lang=zh_cn&edition=full","pubTime":"2024-10-30 10:50","pubTimestamp":1730256637,"startTime":"0","endTime":"0","summary":"   * BioMarin Pharmaceutical Inc   公布的截至1月1日的季度调整后每股收益为55美分，高于去年同期的每股收益21美分。华尔街预期为每股收益 29 美分至 69 美分。* BioMarin Pharmaceutical Inc公布的本季度每股收益为55美分。* 公司报告的季度净收入为 1.0608 亿美元。* BioMarin Pharmaceutical Inc 本季度股价下跌了 0.2%，今年迄今为止下跌了 27.3%。华尔街对 BioMarin Pharmaceutical Inc 的 12 个月目标价中位数为 93.00 美元。本摘要由 LSEG 于世界协调时 10 月 30 日上午 02:49 的数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioMarin Pharmaceutical Inc 报告截至 1 月 1 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4139","BMRN","IE00B19Z3581.USD","BK4566"],"gpt_icon":0},{"id":"2468755283","title":"BUZZ-Ascendis Pharma 发行 3 亿美元股票后业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2468755283","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468755283?lang=zh_cn&edition=full","pubTime":"2024-09-19 04:29","pubTimestamp":1726691372,"startTime":"0","endTime":"0","summary":"    9月18日 - ** 在美国上市的Ascendis Pharma  因寻求股票融资而在延时交易中下跌4.3%，报142.50美元。** 总部位于丹麦的生物制药公司宣布  发行 3 亿美元的美国存托股票** 摩根大通、摩根士丹利、Evercore 和高盛为联合账簿管理人** 周一，ASND 公司称其软骨发育不全疗法 TransCon CNP 在治疗侏儒症的试验中达到了主要目标 ，ASND 股价收盘上涨约 17%，报 139.57 美元。** 在美国上市的股票今年累计上涨约 18%，过去 12 个月累计上涨约 50","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930490.SGD","LU0256863811.USD","IE0034235188.USD","BK4581","BK4588","LU0203345920.USD","IE00B1XK9C88.USD","IE00BBT3K403.USD","BMRN","LU","LU0320765646.SGD","LU1363072403.SGD","LU0211327993.USD","BK4516","BK4566","LU0170899867.USD","BK4504","LU0211331839.USD","LU0267386448.USD","LU1261432733.SGD","BK4585","LU0971096721.USD","LU0496365809.HKD","LU0215105999.USD","IE00BJTD4N35.SGD","LU0203347892.USD","LU0149725797.USD","LU0323591593.USD","IE00BHPRN162.USD","LU1244550221.USD","BK4550","LU0310799852.SGD","LU0106831901.USD","IE00B1BXHZ80.USD","LU0211326755.USD","BK4139","BK4207","IE0002270589.USD","LU0882574139.USD","LU0320765489.SGD","IE00BJTD4V19.USD","IE00BFXG1179.USD","LU1496350171.SGD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","IE00B775SV38.USD","LU0211328371.USD","IE00B3S45H60.SGD","IE00BKVL7J92.USD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2468823343","title":"BUZZ-Ascendis因侏儒症疗法试验数据良好而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2468823343","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468823343?lang=zh_cn&edition=full","pubTime":"2024-09-17 01:13","pubTimestamp":1726506798,"startTime":"0","endTime":"0","summary":"    9月16日 - ** 在美国上市的丹麦Ascendis Pharma    股价上涨17.3%至139.88美元** ASND称其软骨发育不全疗法TransCon CNP达到了主要目标，在一项试验中显示平均生长速度为5.89厘米/年，而安慰剂为4.41厘米/年。** 软骨发育不全症是一种由基因突变引起的短肢侏儒症。** 我们预计TransCon会影响Voxzogo的市场份额，但考虑到TransCon每周的用药情况，我们认为Voxzogo在不同年龄/适应症的总体机会基本不受影响，BMRN的反应过度了。** BMRN 股价在下午交易中下跌 15.1 ** 年初至今，ASND上涨11.3%，BMRN下跌25.8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4139","BMRN","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4566","IE0002270589.USD"],"gpt_icon":0},{"id":"2465954512","title":"美国研究综述-可口可乐、KB Home、纽马克集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2465954512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465954512?lang=zh_cn&edition=full","pubTime":"2024-09-05 20:52","pubTimestamp":1725540777,"startTime":"0","endTime":"0","summary":"    路透9月5日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括可口可乐、KB Home 和 Newmark Group。* 可口可乐公司   ：CFRA将其评级从 \"买入 \"下调至 \"持有 * KB Home   ：加拿大皇家银行将其评级从 \"行业表现 \"下调至 \"表现不佳\"。* 纽马克集团  ：KBW将其评级从 \"市场表现 \"上调至 \"跑赢大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","CE","BASE","BBCP","ATYR","KB","LU1868837136.USD","LU1951198990.SGD","JILL","ABUS","CMA","ARCB","HUM","CASY","LZ","NMRK","LU1868836591.USD","CCEC","MRCY","BK4086","DKS","AVAH","PLAY","BMRN","LU1732800096.USD","KREF","CHPT","BK4543","LH","CACI","ODFL","GNK","OS","LU2286300806.USD","LU1093756168.USD","KO","X","CNM","CARR","LOAR","JWN","CPT","CIEN","KBH","AVAV"],"gpt_icon":1},{"id":"2463250406","title":"拜玛林制药(BMRN)涨超1% 拟在全球裁员约225人","url":"https://stock-news.laohu8.com/highlight/detail?id=2463250406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463250406?lang=zh_cn&edition=full","pubTime":"2024-08-29 22:43","pubTimestamp":1724942609,"startTime":"0","endTime":"0","summary":"金吾财讯 | 拜玛林制药(BMRN)涨超1%，截至发稿，报91.98美元。消息面上，拜玛林制药将在全球裁员约225人。该决定是在该公司更新血友病基因疗法Roctavian战略以及停止其基因疗法BMN 293开发项目之后做出的。本月早些时候，拜玛林制药表示，它将把Roctavian的商业运营重点重新放在三个关键市场上，即美国、德国和意大利。裁员预计将在2024年底基本完成。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"279432","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3B42.SGD","BK4139","IE00B19Z3581.USD","IE0002270589.USD","BMRN","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2463412684","title":"BioMarin 全球裁员约 225 人","url":"https://stock-news.laohu8.com/highlight/detail?id=2463412684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463412684?lang=zh_cn&edition=full","pubTime":"2024-08-29 05:09","pubTimestamp":1724879367,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透8月28日 - 周三提交的一份文件显示，BioMarin Pharmaceutical   已决定在全球范围内裁员约225人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4139","IE00B7SZLL34.SGD","IE0002270589.USD","BMRN","BK4566"],"gpt_icon":0},{"id":"2461009825","title":"美国研究综述-Agree Realty、Global Payments、Snowflake","url":"https://stock-news.laohu8.com/highlight/detail?id=2461009825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461009825?lang=zh_cn&edition=full","pubTime":"2024-08-21 21:23","pubTimestamp":1724246592,"startTime":"0","endTime":"0","summary":"    路透8月21日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Agree Realty、Global Payments 和 Snowflake。要闻  * Agree Realty Corp   ：雷蒙德-詹姆斯将目标价从70美元上调至81美元 * Coinbase Global Inc   ：杰富瑞将目标价从245美元下调至220美元 * Global Payments Inc   ：杰富瑞将目标价从 120 美元上调至 130 美元 * Quest Diagnostics Inc   ：摩根大通将目标价从155美元上调至173美元 * Snowflake Inc   ：贝尔德将目标价从200美元下调至165美元 以下是路透周三报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPR","AXP","CDNA","CPB","CI","EPRT","LU0310800965.SGD","ATI","GNL","GLW","COR","LU1861559042.SGD","FIVN","CHWY","BMRN","ASND","CAH","COIN","BK4205","EOSE","EQIX","BOC","DBRG","CX","LU2552382215.SGD","BK4585","ADC","AADI","DNMR","BK4196","LU0211328371.USD","PINE","LU0011850046.USD","AEO","CCOI","LU1861558580.USD","ADSK","BV","SNOW","ACIW","CIFR","FCPT","COTY","CIVI","DOCS","GLPI","CHRD","IE0004445015.USD","DEI"],"gpt_icon":1},{"id":"2458692651","title":"拜玛林制药2024财年第二财季实现净利润1.07亿美元，同比增加90.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458692651","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458692651?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:07","pubTimestamp":1723392445,"startTime":"0","endTime":"0","summary":"8月12日，拜玛林制药公布财报，公告显示公司2024财年第二财季净利润为1.07亿美元，同比增加90.94%；其中营业收入为7.09亿美元，同比增加19.16%，每股基本收益为0.56美元。从资产负债表来看，拜玛林制药总负债17.81亿美元，其中短期债务5.06亿美元，资产负债比为3.97，流动比率为3.06。机构评级：截至2024年8月12日，当前有24家机构对拜玛林制药目标价做出预测，其中目标均价为109.82美元，其中最低目标价为72.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120007289f2223fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120007289f2223fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN"],"gpt_icon":0},{"id":"2457407515","title":"Scotiabank：维持Biomarin Pharmaceutical(BMRN.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由85.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457407515","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457407515?lang=zh_cn&edition=full","pubTime":"2024-08-07 00:39","pubTimestamp":1722962391,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMRN","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4139","BK4566"],"gpt_icon":0},{"id":"2457732550","title":"BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX","url":"https://stock-news.laohu8.com/highlight/detail?id=2457732550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457732550?lang=zh_cn&edition=full","pubTime":"2024-08-07 00:30","pubTimestamp":1722961818,"startTime":"0","endTime":"0","summary":"美东时间12:14，道琼斯工业平均指数  上涨1.22%，报39,175.66点。标普500指数  上涨1.74%，报5276.66点；纳斯达克综合指数  上涨1.81%，报16492.856点。** CVS Health Corp   ：下跌 0.5%BUZZ - 巴克莱认为，成本上升趋势对 CVS 第二季度和全年利润构成风险   ** Jacobs Solutions Inc   ：上涨 1.2%BUZZ - 在第三季度收入超预期后上涨   ** IDEXX Laboratories Inc   ：上涨 4.3%BUZZ - 在预期下调并不像人们担心的那样糟糕之后，在缓解性反弹中上涨   标准普尔 500 指数的 11 个主要行业：通信服务","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCK","ZTS","SRPT","CAT","DDM","TQQQ","ZI","DXD",".DJI","MKTX","BVS","OGN","TAP","NQmain","J","CSX","EXPD","SQQQ","HIMS","BAX",".IXIC","KVUE",".SPX","TALK","BMRN","TDG","LUMN","FIS","DJX","IDXX","PSQ","HSIC","BUZZ","QID","UDOW","GEHC","BR","SDOW","MNQmain","MPC","VNO","SPWR","CVS","ELEV"],"gpt_icon":1},{"id":"2457029682","title":"BUZZ-BioMarin 因投资者称赞血友病基因疗法的新重点而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2457029682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457029682?lang=zh_cn&edition=full","pubTime":"2024-08-06 22:33","pubTimestamp":1722954781,"startTime":"0","endTime":"0","summary":"    8月6日 - ** BioMarin Pharmaceutical   股价上涨约 8%，创下 86.48 美元的逾三个月新高** BMRN 计划削减血友病基因疗法 Roctavian  的年度直接费用，将商业重点转向美国、德国和意大利市场。** 该公司预计从 2025 年起将 Roctavian 的年度直接费用降至 6000 万美元左右。** Piper Sandler 分析师认为：\"投资者似乎对缩减 Roctavian 支出的决定大加赞赏，因为这将从账面上抹去约 1.2 亿美元的支出\"。** 美国 FDA 去年批准 Roctavian 用于治疗严重 A 型血友病患者** 包括盘中涨幅在内，该股今年累计下跌约 9.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4566","BK4139","BUZZ","IE0002270589.USD","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"1129016401","title":"异动解读 | 拜玛林制药股价大涨7.74%,产品前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1129016401","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129016401?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:49","pubTimestamp":1722952146,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)股价今日盘中大涨7.74%,引发市场关注。分析人士认为,这与投资者对该公司产品销售前景的乐观预期有关。\n\n根据FactSet最新调查,共有17位分析师对拜玛林制药2024年每股收益做出预估,中值由之前的1.88美元上修至1.95美元。同时,分析师预计该公司2024年营收中值为27.89亿美元,较上一年有所增长。这表明分析师对公司未来的盈利能力和产品销售前景更加看好。\n\n一些投资机构认为,拜玛林制药等公司因其强劲的产品收入而被低估,在市场大幅下跌时可提供一定保护。公司的一些新产品前景广阔,有望带动未来收入和利润的持续增长,从而吸引了投资者的资金流入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":-0.0328},{"period":"1month","weight":-0.1004},{"period":"3month","weight":-0.2952},{"period":"6month","weight":-0.1598},{"period":"1year","weight":-0.2824},{"period":"ytd","weight":-0.3419}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.位于特拉华州，研发生产创新生物技术药物，治疗严重的疾病和健康问题。拜玛琳公司选择候选产品时，选择还未解决的具有重大意义的疾病和问题，对生物学有充分的认识，有机会率先面市或者使现有产品得到重大改进。公司产品组合包括四项定型产品和多项临床试验的候选产品。公司的定型产品分别是Naglazyme（加硫酶），Kuvan（二盐酸沙丙蝶呤），Firdapse（药磷酸阿米吡啶）和Aldurazyme（拉罗尼酶）。公司于1996年在特拉华州注册，于1997年3月21号运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.68,"avgChangeRate":0.053118},{"month":2,"riseRate":0.44,"avgChangeRate":0.00883},{"month":3,"riseRate":0.48,"avgChangeRate":0.00524},{"month":4,"riseRate":0.52,"avgChangeRate":-0.015671},{"month":5,"riseRate":0.52,"avgChangeRate":0.009961},{"month":6,"riseRate":0.64,"avgChangeRate":0.01979},{"month":7,"riseRate":0.64,"avgChangeRate":0.039011},{"month":8,"riseRate":0.538462,"avgChangeRate":0.00179},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.010547},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.02699},{"month":11,"riseRate":0.769231,"avgChangeRate":0.0604},{"month":12,"riseRate":0.64,"avgChangeRate":0.034986}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}